These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38558508)

  • 41. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS).
    Misra A; Patel M; Agarwal P; Lodha S; Tandon N; Magdum M; Yajnik C; Ghosh R; Walekar A
    Diabetes Technol Ther; 2019 Nov; 21(11):656-664. PubMed ID: 31335198
    [No Abstract]   [Full Text] [Related]  

  • 42. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study.
    Ji L; Gao L; Cheng Z; Ma G; Li S; Wang H; Liu J; Lu Y; Liu M; Geng J; Gao Y; Ling H; Sun W; Song C; Sun J
    Curr Med Res Opin; 2024 Oct; 40(10):1697-1703. PubMed ID: 39235266
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
    Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
    Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical effectiveness of Novolin® 30R versus Lantus® combined with Glucobay® treatment in elderly patients with type 2 diabetes mellitus controlled by oral hypoglycaemic agents: A randomized study.
    Sun Y; Shao L; Niu X; Liu Y; Ge J; Jiang H; Zhang H
    J Int Med Res; 2014 Aug; 42(4):993-1001. PubMed ID: 24925584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
    Terauchi Y; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T
    Diabetes Obes Metab; 2016 Apr; 18(4):366-74. PubMed ID: 26662838
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness, safety and treatment adherence of biosimilar follow-on insulin in diabetes management.
    Pham TT; Chen X; Barron J; Hart R; Abarca J; DeVries A
    Diabetes Obes Metab; 2022 Oct; 24(10):1989-1997. PubMed ID: 35670655
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of coadministration of sitagliptin with insulin glargine in type 2 diabetes.
    Cao Y; Gao F; Zhang Q; Xu L; Wan Q; Li W; Li J; Wang L; Xue Y
    J Diabetes; 2017 May; 9(5):502-509. PubMed ID: 27255431
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of clinical efficacy and economic value in Basalin- and Lantus-treated patients with type 2 diabetes using continuous glucose monitoring system.
    Li HQ; Lu CF; Wang J; Yin GP; Sun R; Xu XH; Liu BL; Li FF; Jing T; Lee KO; Ye L; Ma JH; Su XF
    J Endocrinol Invest; 2018 Feb; 41(2):179-184. PubMed ID: 28643298
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
    Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
    Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
    Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
    Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.
    Lamb YN; Syed YY
    BioDrugs; 2018 Feb; 32(1):91-98. PubMed ID: 29368288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
    Davies M; Lavalle-González F; Storms F; Gomis R;
    Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V).
    Liu J; Jiang X; Xu B; Wang G; Cui N; Zhang X; Liu J; Mu Y; Guo L
    Adv Ther; 2020 Apr; 37(4):1675-1687. PubMed ID: 32130661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.
    Pan CY; Sinnassamy P; Chung KD; Kim KW;
    Diabetes Res Clin Pract; 2007 Apr; 76(1):111-8. PubMed ID: 17011662
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
    Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Brown-Frandsen K; Moses A; Skibsted S; Kvist K; Buse JB;
    N Engl J Med; 2017 Aug; 377(8):723-732. PubMed ID: 28605603
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.